89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in industry regulatory affairs, product development, and quality to the company.

“We are pleased to welcome Dr. Teresa Perney to our executive leadership team at this critical time for 89bio,” said Rohan Palekar, CEO of 89bio. “As we advance pegozafermin through multiple global Phase 3 studies, Dr. Perney’s extensive expertise in regulatory affairs, product development and quality assurance will be instrumental in shaping our global regulatory strategy. Her addition to our team significantly strengthens our ability to execute on our strategic objectives and potentially accelerate the delivery of pegozafermin to patients in need worldwide.”